GO
Loading...

Actavis Inc

More

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. It will compete with Nektar Therapeutics and AstraZeneca Plc's oral drug Movantik, approved by the FDA earlier this month for the same patient population.

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. Salix, which is merging with Cosmo Pharmaceuticals SpA's Irish subsidiary, is in talks with Allergan Inc and Actavis Plc about a potential sale, sources have told Reuters in recent weeks.

  • Sept 26- T. Rowe Price, the second largest shareholder in Allergan Inc, said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board's corporate governance.

  • NEW YORK, Sept 24- Actavis Plc has reached an agreement with New York's attorney general to keep selling a top Alzheimer's drug for 60 days so U.S. patients will not be forced to switch to a newer, more expensive form of the drug with additional patent protection.

  • CORRECTED-Actavis in buyout talks with Salix - CNBC Wednesday, 24 Sep 2014 | 10:16 AM ET

    Allergan Inc has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals Inc.. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.

  • Allergan in buyout talks with Actavis - CNBC Wednesday, 24 Sep 2014 | 9:54 AM ET

    Sept 24- Allergan Inc is in buyout talks with Actavis Plc in addition to Salix Pharmaceuticals Ltd, CNBC reported on Wednesday, as the company tries to fend off a takeover attempt by Valeant Pharmaceuticals Inc. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.

  • Sept 23- Pfizer Inc has approached Dublin- based generic drugmaker Actavis Plc to express its interest in an acquisition, Bloomberg reported, citing people with knowledge of the matter. The companies are not currently in formal talks and Pfizer has not made an offer, the Bloomberg report said.

  • NEW YORK, Sept 16- Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA, and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Last year Hertz adopted a so-called poison pill to prevent any one shareholder from gaining control of the company as activist investors began circling.

  • Icahn reveals stake in Hertz, plans to push management Wednesday, 20 Aug 2014 | 5:04 PM ET

    BOSTON, Aug 20- Billionaire investor Carl Icahn said on Wednesday that he owns an 8.5 percent stake in Hertz Global Holdings Inc and plans to pressure the rental car company's management over accounting issues and operational failures.

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Aug 5- Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading. Actavis said it expects profit of $13.02- $13.32 per share for the year ending x, below Wall Street estimates of $13.73 per share. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • Drugmaker Actavis posts 34 pct rise in revenue Tuesday, 5 Aug 2014 | 7:36 AM ET

    Aug 5- Generic drug maker Actavis Plc's quarterly revenue rose 34 percent due to strong growth in its North America business. The company had a net profit of $48.7 million, or 28 cents per share, attributable to shareholders for the second quarter ended June 30. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Hedge fund manager Cooperman says market gains will slow Wednesday, 16 Jul 2014 | 12:19 PM ET

    NEW YORK, July 16- Hedge fund manager Leon Cooperman, who has forecast that the Standard& Poor's 500 stock index will hit 2000 this year, cautioned on Wednesday that gains will be slower as the market is more fairly valued now.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.